February 14th 2025
Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
What’s Required in Order to Fight Medication Use Quality Disparities
May 6th 2022When it comes to making equity improvements and successes sustainable, leadership from the top levels are required, and that means finding champions who are bold, open to collaboration, and willing to explore new partnerships with an open mind, the panel agreed.
Read More
Machine Learning Identifies Predictors of Revision Endoscopic Sinus Surgery
May 5th 2022A machine learning approach identified age and several comorbidities, such as nasal polyps and asthma, as being associated with revision endoscopic sinus surgery among patients with chronic rhinosinusitis.
Read More
At PQA, CMS Veteran Blum Highlights Policy Shifts and Rationale for Latest Rulemaking
May 5th 2022Future quality conversations must recognize what the pandemic has illustrated over the past 2 years—that patients who were in the most dire need of health care, including those with multiple chronic conditions, had the least amount of access, said Jonathan Blum, MPP, the principal deputy administrator and chief operating officer of CMS.
Read More
Overlapping Comorbidity Risks Found in Patients With Plaque Psoriasis, Palmoplantar Pustulosis
May 5th 2022An overlapping comorbidity profile was observed among patients with plaque psoriasis and palmoplantar pustulosis, although risks of certain comorbid conditions varied between the 2 groups.
Read More
Patients, Pharmacists Tackle SDOH, With Surprising Insights
May 4th 2022At the Pharmacy Quality Alliance (PQA) 2022 Annual Meeting Wednesday, participants heard about some unexpected insights arising from a workshop held this week between patients and pharmacists who are creating a patient-centered outcomes research agenda focused on addressing social determinants of health (SDOH) in the community pharmacy setting.
Read More
High Disability Burden of Atopic Dermatitis Linked With Socioeconomic Status
May 4th 2022Atopic dermatitis was associated with the greatest burden of disease compared with 2 other types of dermatitis, in which high incidence and disability-adjusted life-years rates corresponded with high sociodemographic index areas.
Read More
Clinical Improvement of AERD Achieved With Dupilumab Use for Asthma, CRS With Nasal Polyps
May 3rd 2022Patients with aspirin-exacerbated respiratory disease (AERD) who initiated treatment with dupilumab as an add-on asthma or chronic rhinosinusitis with nasal polyps therapy reported rapid clinical improvement that was sustained after 3 months.
Read More
Cardiovascular Risk Significantly Greater in Patients With Psoriatic Disease
May 2nd 2022A significantly greater risk of cardiovascular events was observed among a multiethnic Brazilian population of patients with psoriasis and psoriatic arthritis vs controls, in which those in the sixth decade of life had the highest risk.
Read More
The FDA sets a tentative date for a decision on authorizing a COVID-19 vaccine in children under 5 years of age; the American Academy of Pediatrics will review all of its guidance for unproven race-based recommendations contributing to health disparities; the FDA rejects 2 China-tested cancer treatments.
Read More
HPV Infection May Increase Risk of Developing CRS With Nasal Polyps
April 30th 2022Presence of human papillomavirus (HPV) was significantly associated with incidence of chronic rhinosinusitis with nasal polyps (CRSwNP), although no differences in disease severity were observed among HPV-positive and HPV-negative patients with CRSwNP.
Read More
Real-world Patients Show Significant Improvement With Dupilumab for CRS With Nasal Polyps
April 28th 2022Use of dupilumab was associated with significant improvement in clinical symptoms of chronic rhinosinusitis (CRS) with nasal polyps among real-world patients in Canada, with benefits shown to be similar to that observed in randomized clinical trials.
Read More
Avalere's Ryan Urgo on the Biden Administration's Options to Tackle Drug Pricing
April 28th 2022Avalere is presenting at Asembia’s 2022 Specialty Pharmacy Summit, and Ryan Urgo, MPAP, managing director, health policy, discusses possible drug pricing policy options on the table for the Biden administration to consider in a midterm election year.
Watch
Dr Robert Sidbury on Mental Health Implications of Atopic Dermatitis
April 28th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on the mental health comorbidity risk linked with atopic dermatitis and how dermatologists can play a role in managing behavioral care needs of at-risk patients.
Watch
Nathan H. Walcker on Expectations for Stakeholders Attending Tampa IVBM Meeting
April 27th 2022Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute (FCSRI), discusses what guests can expect at the in-person Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by FCSRI.
Watch
Dr Michael Diaz Previews In-person Tampa IVBM Meeting
April 26th 2022Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, previews the Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), cohosted by Florida Cancer Specialists & Research Institute.
Watch
Elevated prevalence of post-traumatic stress disorder seen in family members of patients with COVID-19 treated in intensive care units; 9 rare respiratory cancers linked with burn pit exposure among veterans; adenovirus suggested as potential cause of unexplained cases of pediatric hepatitis.
Read More
Surveyed Patients Identify Unmet Needs in CRS With Nasal Polyps
April 23rd 2022Patients with chronic rhinosinusitis (CRS) with nasal polyps identified several unmet needs regarding their condition, particularly a lack of public and physician awareness on disease burden and poor sleep quality.
Read More
Dr Stephen Rozzo Discusses Real-world Efficacy of Tildrakizumab for Psoriasis
April 22nd 2022Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed findings of 2 phase 4 real-world studies on tildrakizumab, which showed that patients achieved significant improvement in severity and quality of life by week 4 of treatment.
Watch